Related Experiment Videos
Apoptosis as a biomarker in chemoprevention trials
1Division of Cellular Regulation, Promega Corporation, Madison, Wisconsin 53711, USA
Abstract:
Monitoring apoptosis in histologic samples is becoming increasingly important as more effort is applied to the study of therapeutic modulators of cell death in tumors. The common methods used to monitor DNA fragmentation and cell morphology as markers of apoptosis have their own set of advantages and disadvantages. Growing knowledge of the signaling events that occur during cell death has established the caspase enzymes as the central executioner proteases of apoptosis. The results of caspase activity generate neo-epitopes that occur only during apoptosis. Directly monitoring caspase-mediated events as markers of apoptosis offers advantages over existing assay methods. Recently, several new marker antibodies have been developed that detect active caspase enzymes or the products they produce. The possibility of using these new marker antibodies for monitoring prostate chemoprevention trials is presented in this review.
Insights
New antibodies targeting active caspases offer a direct method for monitoring apoptosis. This approach provides advantages over traditional DNA fragmentation assays for studying cell death in tumors and chemoprevention trials.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Monitoring apoptosis (programmed cell death) in tumor tissues is crucial for evaluating cancer therapies.
- Traditional methods like DNA fragmentation assays have limitations.
- Caspase enzymes are key executioners of apoptosis, generating unique markers upon activation.
Purpose of the Study:
- To review the advantages of directly monitoring caspase activity for apoptosis detection.
- To introduce novel marker antibodies that detect active caspases or their products.
- To discuss the utility of these antibodies in prostate cancer chemoprevention studies.
Main Methods:
- Review of existing literature on apoptosis detection methods.
- Discussion of newly developed antibodies targeting activated caspases.
- Exploration of the application of these antibodies in preclinical and clinical settings.
Main Results:
- Caspase activation generates specific neo-epitopes detectable by new antibodies.
- These antibodies offer a direct and potentially more sensitive method for apoptosis monitoring.
- The use of these markers in chemoprevention trials is feasible and advantageous.
Conclusions:
- Direct detection of caspase-mediated events represents an advancement in apoptosis monitoring.
- Novel caspase-targeting antibodies show promise for evaluating therapeutic modulators of cell death.
- These markers can enhance the assessment of prostate cancer chemoprevention strategies.